Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics by Varoquaux, Arthur et al.
HAL Id: hal-01414336
https://hal-amu.archives-ouvertes.fr/hal-01414336
Submitted on 9 Dec 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Magnetic resonance spectroscopy of paragangliomas:
new insights into in vivo metabolomics
Arthur Varoquaux, Yann Le Fur, Alessio Imperiale, Antony Reyre, Marion
Montava, Nicolas Fakhry, Izzie-Jacques Namer, Guy Moulin, Karel Pacak,
Maxime Guye, et al.
To cite this version:
Arthur Varoquaux, Yann Le Fur, Alessio Imperiale, Antony Reyre, Marion Montava, et al.. Magnetic
resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. Endocrine-Related
Cancer, BioScientifica, 2015, 22 (4), pp.M1-8. ￿10.1530/ERC-15-0246￿. ￿hal-01414336￿
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Thematic Research
A Varoquaux et al. MRS for PGL imaging 22 :4 M1–M8Magnetic resonance spectroscopy
of paragangliomas: new insights
into in vivo metabolomicsArthur Varoquaux1, Yann le Fur2, Alessio Imperiale3,4, Antony Reyre1,
Marion Montava5, Nicolas Fakhry6, Izzie-Jacques Namer3,4, Guy Moulin1, Karel Pacak7,
Maxime Guye1,2 and David Taı¨eb8,9,10
1Department of Medical Imaging, La Timone University Hospital, Aix-Marseille University, Marseille, France
2CNRS, CRMBM UMR 7339, Aix-Marseille University, 13385 Marseille, France
3Department of Biophysics and Nuclear Medicine, University Hospitals of Strasbourg, Strasbourg, France
4ICube, UMR 7357, Faculty of Medicine, University of Strasbourg/CNRS and FMTS, Strasbourg, France
5Department of Otorhinolaryngology–Head and Neck Surgery, North Hospital, Aix-Marseille University,
Marseille, France
6Department of Otorhinolaryngology–Head and Neck Surgery, La Timone University Hospital, Aix-Marseille
University, Marseille, France
7Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and
Human Development (NICHD), National Institutes of Health, Bethesda, Maryland 20892, USA
8Department of Nuclear Medicine, La Timone University Hospital, Aix-Marseille University, Marseille, France
9Biophysics and Nuclear Medicine, European Center for Research in Medical Imaging, La Timone University Hospital,
Aix-Marseille University, 264, Rue Saint-Pierre, 13385 Marseille, France
10INSERM, UMR1068, Institut Paoli-Calmettes, Marseille Cancerology Research Center, Marseille, Francehttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0246 Printed in Great Britain
Published by Bioscientifica Ltd.
DownloaCorrespondence
should be addressed
to D Taı¨eb or A Varoquaux
Emails
david.taieb@ap-hm.fr or
DamienArthur.
VAROQUAUX@ap-hm.frAbstractParagangliomas (PGLs) canbe associated with mutations ingenes of thetricarboxylic acid (TCA)
cycle. Succinate dehydrogenase (SDHx) mutations are the prime examples of genetically
determined TCA cycle defects with accumulation of succinate. Succinate, which acts as an
oncometabolite, can be detected by ex vivo metabolomics approaches. The aim of this study
was to evaluate the potential role of proton magnetic resonance (MR) spectroscopy (1H-MRS)
for identifying SDHx-related PGLs in vivo and noninvasively. Eight patients were prospectively
evaluated with single voxel 1H-MRS. MR spectra from eight tumors (four SDHx-related PGLs,
two sporadic PGLs, one cervical schwannoma, and one cervical neurofibroma) were acquired
and interpreted qualitatively. Compared to other tumors, a succinate resonance peak was
detected only in SDHx-related tumor patients. Spectra quality was considered good in three
cases, medium in two cases, poor in two cases, and uninterpretable in the latter case. Smaller
lesions had lower spectra quality compared to larger lesions. Jugular PGLs also exhibited a
poorer spectra quality compared to other locations. 1H-MRS has always been challenging in
terms of its technical requisites. This is even more true for the evaluation of head and neck
tumors. However, 1H-MRS might be added to the classical MR sequences for metabolomic
characterization of PGLs. In vivo detection of succinate might guide genetic testing,
characterize SDHx variants of unknown significance (in the absence of available tumor sample)
, and even optimize a selection of appropriate therapies.Key Words
" MR-spectroscopy
" paraganglioma
" positron-emission
tomography
" metabolomicsdedEndocrine-Related Cancer
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Thematic Research A Varoquaux et al. MRS for PGL imaging 22 :4 M2IntroductionParagangliomas (PGLs) are slow-growing hypervascular
tumors arising from neural crest cell derivatives through-
out the body. PGLs are closely aligned with the distri-
bution of the autonomic nervous system and
preferentially arise in the adrenal medulla, along the
thoracoabdominopelvic sympathetic system, or in para-
sympathetic paraganglia that are mainly located in the
head and neck (Taieb et al. 2014a).
Approximately 30–40% of PGLs carry a germ line
mutation, which frequently occurs in one of the succinate
dehydrogenase (SDH) subunit genes (collectively referred
to as SDHx) (Baysal et al. 2002, Neumann et al. 2009,
Piccini et al. 2012, Martucci & Pacak 2014).
The SDH complex (also named mitochondrial
complex II) catalyzes the oxidation of succinate to
fumarate in the tricarboxylic acid (TCA) cycle and the
respiratory chain. Deleterious mutations in any of the
SDH genes (after biallelic inactivation) invariably result in
decreased SDH activity, with accumulation of succinate,
which acts as an oncometabolite (Selak et al. 2005).
We, and others, have recently shown that ex vivo
metabolomics studies are very reliable methods for classify-
ing various pheochromocytomas (PHEOs)/PGLs according
to their genetic background (Imperiale et al. 2013a, Richter
et al. 2014, Rao et al. 2015). Assessment of succinate
concentration and succinate:fumarate ratio can be clinically
relevant for discriminating SDHx-related tumors from
sporadic and other hereditary PHEOs/PGLs (Lendvai et al.
2014, Richter et al. 2014, Imperiale et al. 2015a). These
studies nicely pointed toward the importance of metabolite
profiling in the evaluation of these tumors.
In recent years, anatomic and functional imaging
techniques have gained an increasing role in the character-
ization of PHEOs/PGLs (Taieb et al. 2013, 2014a). The use
of magnetic resonance imaging (MRI) as a non-ionizing
technique is rapidly growing in the evaluation of PGLs
with clinical implementation of multiparametric
sequences that provide relevant biological information
(i.e., diffusion weighted imaging, dynamic contrast
enhancement, and spectroscopy). MR spectroscopy (MRS)
enables quantification of metabolites in tissues (Bruhn et al.
1989, King et al. 2010). MRS uses intrinsic MR proprieties
of some atomic nuclei (i.e., 1Hydrogen, 31Phosphorous,
19Fluorine, and 13Carbon) placed in a radiofrequency range
of magnetic fields (de Graaf 2008). Proton spectroscopy
(1H-MRS) is available in numerous magnetic field strengths
(currently from 1.5 to 7 Tesla) and has been evaluated in
the characterization of various brain (Fellah et al. 2013) andhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0246 Printed in Great Britainextracerebral tumors (King et al. 2005, Jansen et al. 2012,
Abdel Razek & Poptani 2013).
Currently, there is a strong interest in i) assessing the
genetic and metabolomics backgrounds of tumors based
on their metabolomics profile using noninvasive tech-
niques that would not require obtaining additional tumor
samples (in some patients, especially those with metastatic
PHEO/PGL, it is difficult to obtain because biopsy may be
contraindicated); ii) decreasing radiation exposure of
cancer patients to the repeated use of anatomical and
functional modalities in assessing or monitoring thera-
peutic responses; iii) minimizing the cost to a patient as
well as the health care system by using multiple imaging
modalities; and iv) selecting appropriate treatment
options that are expected in the near future to be largely
based on the assessment of tumor metabolomics profiles
because metabolites are now considered as ‘first-line’
combat soldiers in a cancer cell.
Thus, the aim of the present study was to evaluate the
potential role of 3T proton MRS in identifying various
SDHx-related PGLs and then to compare those results to
other sporadic PGLs or non-PGL tumors.Materials and methods
Patients
Eight consecutive patients with suspicion of either HNPGL
or a neck nerve sheath tumor were evaluated by 1H-MRS
in addition to conventional MR sequences. PGL patients
were included in a large prospective clinical trial
dedicated to positron emission tomography (PET) imaging
studies (NCT02186678) and were therefore evaluated
by 18F-FDOPA and 68Ga-DOTATATE PET/computed
tomography (CT) (patient nos 1–6) using low-dose CT
protocol. The remaining two patients gave their informed
consent for use of their personal data for scientific
purposes, in keeping with local institutional guidelines.MRI protocol
MRI was performed on a 3T MR scanner (Magnetom Skyra,
Siemens Healthcare, Erlangen, Germany) equipped with
a 32-channel phased-array head coil. The signal of mono-
voxel MRS was collected following the unenhanced conven-
tional MR sequences (for head and neck regions: T1, T2, and
time of flight angiography (TOF)). The volume of interest
(VOI) was carefully positioned by a radiologist with 10 years’
experience (A Varoquaux). The VOI was adapted to the sizePublished by Bioscientifica Ltd.
Downloaded from Bioscientifica.com at 12/09/2019 02:50:11PM
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Thematic Research A Varoquaux et al. MRS for PGL imaging 22 :4 M3and geometry and centered within the bulk tumor region,
excluding nearby bone structures. Six outer-volume lipid
suppression bands were used to suppress lipid contami-
nation, and pre-acquisition included shimming and water
suppression. Spectra were acquired with a point-resolved
spectroscopy sequence (PRESS; TE, 135 ms and repetition
time (TR), 2000 ms) using the manufacturer’s automated
shimming procedure. An H2O signal was acquired for
quantification purposes at the samelocation.Extra scanning
time, includingshimmingandacquisition(120excitations),
was 8 min.Post processing
The MRS data were analyzed using a dedicated software
described elsewhere (Le Fur et al. 2010). After Fourier
transformation, the residual water signal was removed
using HLSVD (de Beer et al. 1992). Spectra was fitted using
HRQUEST (Ratiney et al. 2005) with a simulated database
that incorporated seven metabolites selected according
to the HRMAS spectrum (Imperiale et al. 2013a,b, 2015a):
acetate, alanine, glutamate, glutathione, lactate, meth-
ionine, and succinate.
Quality of the spectra were classified as follows: i) good:
thin resonances, good water suppression, and absence of
lipid signal contamination; ii) medium: broad resonances
but clearly distinguishable, acceptable water suppression,
and low lipid contamination; iii) poor: resonances hardly
distinguishable and/or bad water suppression and/or high
lipid signal; and iv) uninterpretable spectrum. MRS spectra
were interpreted by experts blinded to the SDH mutation
status and pathological findings.Table 1 Patient and tumor characteristics, and imaging findings
Patient Diagnosis Status Focality
Location
of the
tumor
assessed
by MRS 18F-FDOPAa
1 PGL SDHD Multi Vagal C
2 PGL SDHD Multi Jugular C
3 PGL SDHB Uni Carotid
body
C
4 PGL SDHD Multi Carotid
body
C
5 PGL Sporadic Uni Jugular C
6 PGL Sporadic Uni Jugular C
7 Neurofibroma – Uni Vagal ND
8 Schwannoma – Uni Vagal ND
ND, not done.
a18F-FDOPA and 68Ga-DOTATATE findings in PGLs evaluated by MRS.
bTumor volumes were measured on contrast-enhanced T1-weighted MR image
http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0246 Printed in Great BritainHRMAS MRS
HRMAS MRS was performed in three cases (carotid body
PGL (CBP) from patient nos 3 and 4 and one abdominal
extra-adrenal PGL from patient no. 1) from the analysis of
a frozen intact tumor sample of about 15 mg. Spectra were
acquired on a Bruker Avance III 500 Spectrometer
(500.13 MHz) (Bruker BioSpin, Wissembourg, France).
One-dimensional (1D) proton and two-dimensional (2D)
heteronuclear (1H-13C) experiments were recorded.
Selected metabolites were quantified according to our
previous reports (Imperiale et al. 2013b).Gold standard
Pathological analysis of the tumor was considered the gold
standard for final diagnosis. When surgery was not
indicated or already performed, lesions were characterized
as PGL by tumor positivity on either 18F-FDOPA or
68Ga-DOTATATE in specific locations, regardless of
genetic background.Results
Patients and tumors
Eight patients (two males and six females, age 30–73 years)
were included in the present study (Table 1). Final
diagnoses included six PGLs, one cervical schwannoma,
and one cervical neurofibroma. Pathological confirmation
was obtained in two PGL and two benign nerve sheath
tumors. In other PGLs, the diagnosis was based on findings68Ga-
DOTATATEa
Tumor
volume
(cm3)b
Gold
standard
Spectra
quality Succinate
C 8.2 Pathology Good Detected
C 2.3 PET imaging Medium Detected
C 19.6 PET imaging Good Detected
C 4.4 Pathology Uninter-
pretable
NA
C 2.1 PET imaging Poor Not detected
C 1.5 PET imaging Poor Not detected
ND 24.9 Pathology Good Not detected
ND 6.7 Pathology Medium Not detected
s using OsiriX Software (v5.6, 64 bit, Geneva, Switzerland).
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Figure 1
Multifocal SDHD-related PGLs (patient no. 1). (A) Axial 68Ga-DOTATATE PET
showing bilateral vagal PGL. (B) Axial plane of pre-acquisition VOI
adaptation before 1H-MRS PRESS, with manual placement of six saturation
bands (only four visible on image) to avoid lipid contamination from the
parapharyngeal space and spine. (C) The acquired spectrum, fitted
spectrum, fitted macromolecules, and residue (i.e., the acquired spectrum
minus the result of the fit) represented from top to bottom. The last line
shows the succinate signal as found by the quantification algorithm.
Other resonances are not shown for reason of clarity. It can be seen on the
residue that some signals are still visible. The metabolite(s) giving these
signals are still not assigned and therefore not present in the database.
(D) 1H-HRMAS MR spectra obtained from the analysis of an abdominal PGL
from this patient showing an obvious peak of succinate (singlet at
2.41 p.p.m.). A full colour version of this figure is available at http://dx.doi.
org/10.1530/ERC-15-0246.
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Thematic Research A Varoquaux et al. MRS for PGL imaging 22 :4 M4from images using various specific tracers. Genetic testing
was performed in all but one PGL and revealed SDHD
mutations in three cases (patient nos 1, 2, and 4) and SDHB
in one case (patient no. 3). Tumors evaluated by MRS were
localized to the jugular foramen in three cases, the
retrostyloid parapharyngeal space in three cases, and the
carotid body in two cases. Mean tumor volume was 8.7 ml
and ranged from 1.5 to 24.9 ml.MRS findings
Spectra quality was considered good in three cases,
medium in two, poor in two, and uninterpretable in the
latter case due to motion artifacts. Smaller lesions had
lower spectra quality compared to larger lesions. JugularA B
O
R
Figure 2
Carotid body SDHB-related PGL (patient no. 3). (A) Axial 18F-FDOPA PET
showing a highly avid CBP. (B) VOI adaptation before 1H-MRS with manual
placement of six saturation bands (only four visible on image). (C) The last
line shows the succinate signal as found by the quantification algorithm.
http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0246 Printed in Great BritainPGL also exhibited a poorer spectra quality compared to
vagal PGL and CBP. A succinate resonance peak was only
detected in SDHx-related tumor patients. Succinate was
detected in patient no. 3, who had a 2.3 ml jugular PGL
with medium quality spectra. Two examples of 1H-MR
spectra in comparison to HRMAS findings are presented
in Figs 1 and 2. A spectra without succinate is shown in
Supplementary Fig. 1 (see section on supplementary data
given at the end of this article).Discussion
The present study demonstrates that 1H-MRS could enable
in vivo detection of succinate in SDHx-related tumors.
These results emphasize that, beyond its localizationC D
riginal
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Macro
esidue
Succinate
3.00 2.00 1.00
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 ppm
ppm
Succinate
(D) 1H-HRMAS MR spectra obtained from the analysis of the CBP showing
an important accumulation of succinate in tumoral tissue (singlet at
2.41 p.p.m.).
Published by Bioscientifica Ltd.
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Thematic Research A Varoquaux et al. MRS for PGL imaging 22 :4 M5value, this imaging modality provides unique opportu-
nities for better characterizing these tumors at a metabo-
lomic level that is uniquely linked to their molecular
signature, in these as well as other tumors. Thus, recently,
it has been proposed that ex vivo detection of succinate and
other metabolites could guide genetic testing (Lendvai
et al. 2014, Richter et al. 2014). In recent years, it has also
been demonstrated that immunohistochemistry using
specific antibodies against SDH subunits is a reliable
method for predicting SDH mutations (van Nederveen
et al. 2009). However, these and other ex vivo techniques
have some limitations because they are not applicable in
cases where PGLs are treated by repeated radiation, cannot
be removed surgically due to their unusual location or size,
and are unable to provide continuous specific metabolite
assessment that would be very useful for monitoring or
predicting changes in intratumoral metabolism, tumor
aggressiveness, resistant or responsive therapy, and meta-
static spread. Therefore, in vivo metabolomics character-
ization of any tumor is becoming of paramount interest
for guiding genetic, therapeutic, and outcome evaluation
of cancer patients.
Metabolomics or metabolite profiling is the youngest
sibling in the family of -omics fields and is growing up.
Maturing right behind genomics, transcriptomics, and
proteomics, metabolomics is the comprehensive analysis
of small molecule metabolites (Reitman et al. 2011).
Succinate is a component of the TCA cycle that serves as
an electron donor to complex II. Succinate is present in the
brain at w0.5 mmol/kg (Klunk et al. 1996). Although
presentat sucha lowconcentration, it contains four protons
from twomethylene groups that all contribute to a singlet at
2.39 p.p.m. In conventional in vivo 1D MRS experiments,
this signal overlaps with resonances of glutamate and
glutamine (Govindaraju et al. 2000). However, using
HRMSAS, we have previously shown that SDHx-associated
PGL exhibits a very low glutamate content (Imperiale et al.
2015a). Increased succinate has also been reported in
human brain abscesses (Shukla-Dave et al. 2001).
Pioneering studies or hypotheses from investigations
by Selak et al. (2005) showed the accumulation of succinate
in SDHx-tumors. Elevated plasma succinate has even been
proposed as a screening test for detecting SDHx mutation-
positive individuals (Hobert et al. 2012). Detection of
succinate has been also found to be very useful for
classifying SDH variants of unknown etiology as patho-
genic or depicting SDH deficiency without an SDHx
mutation such as an SDH promoter methylation that may
occur in some cases like Carney triad (Haller et al. 2014,
Imperiale et al. 2015a). More recently, a significantlyhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0246 Printed in Great Britainincreased succinate:fumarate ratio has also been described
in SDHx-related PGLs and proposed as a new metabolic
marker of these tumors (Lendvai et al. 2014, Richter et al.
2014). Several studies have shown that succinate and
possibly other metabolites, the so-called PHEO/PGL meta-
bolomics milieu, play important and perhaps the most
crucial role in the pathogenesis, behavior, and outcome of
these tumors (Vicha et al. 2014). Thus, beyond SDHx
mutations, disruption of the TCA cycle has been described
for other mutations that predispose to PHEOs/PGLs such as
isocitrate dehydrogenase type 1 (Gaal et al. 2010), fumarate
hydratase (Castro-Vega et al. 2014), and the more recently
described malate dehydrogenase type 2 (Cascon et al.
2015). It is also expected that the detection of other TCA
enzyme mutations may play an important role in the
pathogenesis of PHEO/PGL, and the use of metabolomics to
uncover new PHEO/PGL-specific metabolomic profiles will
become crucial in novel discoveries of such mutations in
the very near future.
High MRS spectra quality, demonstrated by the ability
to separate resonances from important metabolites within
the tumor, depends on various technical aspects such as
voxel and pre-saturation band placement, pre-acquisition
shimming quality, acquisition parameters, water and fat
suppression, and post processing. Compared to the brain,
the MRS of HNPGLs is challenging due to their anatomical
location near or within bone structures and the surround-
ing adipose tissue, which create susceptibility artifacts and
make the shimming process very difficult. Furthermore,
data quality is also degraded by patient motion (head
movement) and vascular pulsatility. In the present study,
jugular PGL and small lesions exhibited a poorer spectra
quality compared to other sites. These PGLs, which arise
from the dome of the jugular vein and are located in the
temporal bone, are more sensitive to susceptibility
artifacts, with specific problems for optimizing shimming
and fat suppression. In one CBP, motion artifacts lead
to an uninterpretable spectrum. A manual shimming
procedure could improve spectral quality but requires
longer examinations.
In our study, smaller lesions were also found to have
lower quality spectra. In these cases, the lower size of the
voxel volume decreased the signal-to-noise ratio (SNR). It is
possible to reduce the voxel size to 1 ml (Abdel Razek &
Poptani 2013), but this requires increasing the number
of excitations with a subsequent increased duration of
the scan.
The present and previous studies open and strengthen
a new field of in vivo metabolomics profiling in various
PHEOs/PGLs. In recent years, 18F-FDG uptake has also beenPublished by Bioscientifica Ltd.
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Thematic Research A Varoquaux et al. MRS for PGL imaging 22 :4 M6shown to be strongly dependent on patient genotype.
Thus, the degree of 18F-FDG uptake has also been
proposed as a predictor of SDHx PHEOs/PGLs (Taieb et al.
2009, 2014b, Timmers et al. 2012, Blanchet et al. 2014).
According to this lesion-based model using SUV ratio and
tumor diameter, sensitivity, specificity, positive predictive
value, negative predictive value, and accuracy were 80.8,
63.6, 83.1, 60.0, and 75.5% respectively (Blanchet et al.
2014). Beyond the practical constraints associated with
MRS, it is anticipated that in vivo detection of succinate
would have a better pneumococcal polysaccharide vac-
cination than 18F-FDG uptake, but this remains to be tested
on a very large population of patients with different genetic
backgrounds.
It is also expected that MRS could be applied to the
metabolite assessment in the setting of adrenal and extra-
adrenal sympathetic PGLs. Even if compared to jugular
foramen localization, the 1H-MRS analysis of the adrenal
region encounters less susceptibility artefacts (dental
fillings, petrous apex pneumatisation), the physiologic
respiratory motion complicates matters. Faria et al. (2007)
showed that adrenal 1H-MRS free breathing point-resolved
multi-voxel acquisition enabled adenomas and PHEOs to
be distinguished from carcinomas and metastases using a
ratio between choline, creatine, and lipids. Most authors
recommend the use of respiratory triggering, which, in
return, needs elaborate and time-consuming post-proces-
sing processes to exploit the spectra (Schwarz & Leach
2000, Katz-Brull et al. 2003, Faria et al. 2007, Kim et al.
2009). Recently, Imperiale et al. (2015b) have confirmed
that respiratory-triggered single-voxel 1H-MRS enables
in vivo detection of catecholamines in PHEOs. We believe
that assessing succinate in the adrenal masses of SDHx
patients will require respiratory-triggered single-voxel
1H-MRS acquisitions with repeated excitations, improving
the sensibility for succinate detection to the detriment of
the examination length.
Several studies have pointed well towards impair-
ments in oxidative phosphorylation processes within
PHEOs/PGLs (Favier et al. 2009, Vicha et al. 2014,
Rao et al. 2015). Phosphorus metabolism (inorganic
phosphate, phospho-creatine, ATP) can be evaluated
in vivo by 31P-MRS (Abdel Razek & Poptani 2013) and,
therefore, should provide new information in the meta-
bolomic/energy characterization of these tumors. The use
of hyperpolarized nuclei may also be an attractive
additional tool for proton MRS because it may increase
the signal factor by 6000 and quality spectra
(increased SNR). Therefore, this enables for in vivo assess-
ment of small tumors in a faster acquisition timehttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0246 Printed in Great Britain(Kurhanewicz et al. 2011). Hyperpolarized succinate can
be produced using para-hydrogen induced polarization
and was thus used as a contrast agent for MRI and MRS
in preclinical studies of brain tumors (Bhattacharya et al.
2007). More recently, it has been shown that hyper-
polarized (2H, 13C)-labeled glucose by dynamic nuclear
polarization increases the SNR up to 10 000 times
(Ardenkjaer-Larsen et al. 2003). This contrast agent could
be used for the assessment of succinate and other TCA
metabolites by MRS (Mishkovsky et al. 2012) and
successfully applied to various hereditary PHEO/PGL that
are considered as a metabolic disease.
In conclusion, in vivo metabolomics analysis may
serve as an important bridge between molecular genetics
and imaging. 1H-MRS could be added to the classical MR
sequences for characterization of various PHEOs/PGLs,
especially those related to TCA cycle impairment.
Imperiale et al. (2015b) have also recently shown that
1H-MRS enables in vivo detection of catecholamines in
PHEOs. The recently introduced PET/MR systems enable
acquisition of MRS and PET data during a single exami-
nation, provide high-quality fusion of both modalities and
potentially provide the opportunity to perform multi-voxel
acquisition analysis in the setting of prospective studies.
In vivo detection of succinate shows promise in further
guiding genetic testing and characterization of SDH
variants, especially in the absence of available tumor
samples and detection of changes in plasma succinate
levels in these patients, which is currently insufficient.
This approach also has the future potential of serving as an
important tool for monitoring therapeutic responses
while avoiding excessive radiation exposure or functional
imaging techniques that are often very costly yet limited
in availability. Nevertheless, the conclusions of the
present study should be tested on a very large population
of patients with SDHx and non-SDHx tumors.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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